# Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

> **NCT00331682** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** alvocidib
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00331682
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331682, "Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00331682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*